Viking Therapeutics, Inc. has a 1 year low of $18.14 and a 1 year high of $99.41. The firm has a market capitalization of $4.74 billion, a PE ratio of -45.73 and a beta of 0.95. Get Viking ...

Hello and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that ...

Brian Lian, Ph.D., CEO of Viking Therapeutics, said the following about the news: “No evidence of a plateau was observed at Week 13 for any VK2735 dose, suggesting further weight loss might be ...

The data released by Viking showed that adults taking the ... effective maintenance of weight control," said Viking CEO Brian Lian, Ph.D., in a statement. Profit and prosper with the best of ...

Viking Therapeutics reports quarterly losses ... and extremely productive year for Viking,” stated Brian Lian, Ph.D., CEO of Viking. “During the year, the company reported positive data ...

Viking held cash, cash equivalents and short-term investments of $903M, compared to $362M as of December 31, 2023. 2024 ...

The transaction, which took... In a recent transaction, Brian Lian, the President and CEO of Viking Therapeutics, Inc. (NASDAQ:VKTX), sold 1,000 shares of the company's common stock. The sale ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...

Welcome to the Viking Therapeutics Fourth Quarter and ... Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that ...